VULVOVAGINAL CANDIDIASIS IN COMBINATION WITH BACTERIAL VAGINOSIS IN WOMEN OF REPRODUCTIVE AGE: FEATURES OF PATHOGENESIS AND TREATMENT
Abstract
The aim. Reducing the recurrence of vulvovaginal candidiasis (VVC) in combination with bacterial vaginosis (BV) in women of reproductive age by studying the pathogenesis and improving the algorithm of treatment and prevention measures.
Materials and methods. During the study, 150 women of reproductive age who had the same clinical manifestations of VVC and BV were selected and divided into 3 groups of 50 women: Group I was treated with an antimicrobial combination drug (miconazole with topical metronidazole), group II – the same drug in combination with probiotic (lactobacilli) in candles, group III – according to the algorithm improved by the authors. In addition, a control group was formed, which included healthy women of reproductive age.
To establish the pathogenesis of VVC in combination with BV in the studied women, the concentration of cytokines and adhesion molecules in the blood before and after treatment was determined and compared with the control group.
The clinical effect of different treatments was assessed at 3, 7, 10, 14 days, and the presence of relapses – 1, 3, 6 months after treatment.
Results. The occurrence of a combination of VVC and BV in women of reproductive age is accompanied by a significant increase in the level of intercellular adhesion molecules (ICAM-1) and vascular cell adhesion molecules (VCAM-1) along with a statistically significant increase in proinflammatory cytokines (interleukin-6) (IL-6), interleukin-8 (IL-8)) and tumor necrosis factor (TNF) - TNF-α. As a result of the application of the algorithm improved by the authors, higher clinical efficiency and the ability to avoid recurrence of VVC in combination with BV in women of reproductive age were obtained.
Conclusions. The authors' substantiated improvement of the algorithm of VVC treatment in combination with BV in women of reproductive age makes it possible to reduce the frequency of their recurrence and restore the biocenosis of the vagina to normal. In the case of this pathology there is an increase in the level of pro-inflammatory cytokines (IL-6, IL-8), TNF-α and ICAM-1 and VCAM-1.
Downloads
References
Van de Wijgert, J. H. H. M., Jespers, V. (2017). The global health impact of vaginal dysbiosis. Research in Microbiology, 168 (9-10), 859–864. doi: http://doi.org/10.1016/j.resmic.2017.02.003
Brown, R. G., Marchesi, J. R., Lee, Y. S., Smith, A., Lehne, B., Kindinger, L. M. et. al. (2018). Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin. BMC Medicine, 16 (1). doi: http://doi.org/10.1186/s12916-017-0999-x
Schlabritz-Loutsevitch, N., Gygax, S. E., Dick, E., Smith, W. L., Snider, C., Hubbard, G., Ventolini, G. (2016). Vaginal Dysbiosis from an Evolutionary Perspective. Scientific Reports, 6 (1). doi: http://doi.org/10.1038/srep26817
Nelson, T. M., Borgogna, J.-L. C., Brotman, R. M., Ravel, J., Walk, S. T., Yeoman, C. J. (2015). Vaginal biogenic amines: biomarkers of bacterial vaginosis or precursors to vaginal dysbiosis? Frontiers in Physiology, 6. doi: http://doi.org/10.3389/fphys.2015.00253
Amabebe, E., Anumba, D. O. C. (2018). The Vaginal Microenvironment: The Physiologic Role of Lactobacilli. Frontiers in Medicine, 5. doi: http://doi.org/10.3389/fmed.2018.00181
Ceccarani, C., Foschi, C., Parolin, C., D’Antuono, A., Gaspari, V., Consolandi, C. et. al. (2019). Diversity of vaginal microbiome and metabolome during genital infections. Scientific Reports, 9 (1). doi: http://doi.org/10.1038/s41598-019-50410-x
Lohse, M. B., Gulati, M., Johnson, A. D., Nobile, C. J. (2017). Development and regulation of single- and multi-species Candida albicans biofilms. Nature Reviews Microbiology, 16 (1), 19–31. doi: http://doi.org/10.1038/nrmicro.2017.107
Dadar, M., Tiwari, R., Karthik, K., Chakraborty, S., Shahali, Y., Dhama, K. (2018). Candida albicans – Biology, molecular characterization, pathogenicity, and advances in diagnosis and control – An update. Microbial Pathogenesis, 117, 128–138. doi: http://doi.org/10.1016/j.micpath.2018.02.028
Polidanov, M. A., Blokhin, I. S., Skorokhod, A. A., Alieva, S. G., Scherbakova, I. V. (2020). Poniatie i znachenie kriteriia stiudenta v klinicheskoi meditsine. Modern Science, 2-1, 227–230.
Mintser O. P. (2017). Statystychni metody doslidzhen pry vykonanni naukovykh doslidzhen. Praktychna medytsyna, 7, 43–50.
Pandey, S. A. (2020). Combination of candida vulvovaginitis and bacterial vaginosis: optimization of diagnostics and treatment for the women of genesial age. Reproductive health of woman, 3, 32–35. doi: http://doi.org/10.30841/2708-8731.3.2020.215012
M.M., R. (2020). Clinical And Epidemiological Features Of Bacterial Vaginosis. The American Journal of Medical Sciences and Pharmaceutical Research, 2 (8), 140–145. doi: http://doi.org/10.37547/tajmspr/volume02issue08-21
Li, J., McCormick, J., Bocking, A., Reid, G. (2012). Importance of Vaginal Microbes in Reproductive Health. Reproductive Sciences, 19 (3), 235–242. doi: http://doi.org/10.1177/1933719111418379
Lubkovska, O. (2020). Comparative aspects of placental dysfunction in women using different methods of contraception in anamnesis. EUREKA: Health Sciences, 5, 34–40. doi: http://doi.org/10.21303/2504-5679.2020.001416
Zheng, N., Guo, R., Yao, Y., Jin, M., Cheng, Y., Ling, Z. (2019). Lactobacillus iners Is Associated with Vaginal Dysbiosis in Healthy Pregnant Women: A Preliminary Study. BioMed Research International, 2019, 1–9. doi: http://doi.org/10.1155/2019/6079734
De Seta, F., Campisciano, G., Zanotta, N., Ricci, G., Comar, M. (2019). The Vaginal Community State Types Microbiome-Immune Network as Key Factor for Bacterial Vaginosis and Aerobic Vaginitis. Frontiers in Microbiology, 10. doi: http://doi.org/10.3389/fmicb.2019.02451
Hruzevskyi, O. (2020). The cytokine system’s status in bacterial dysbiosis and bacterial vaginosis. ScienceRise: Medical Science, 3 (36), 50–56. doi: http://doi.org/10.15587/2519-4798.2020.204094
Masson, L., Barnabas, S., Deese, J., Lennard, K., Dabee, S., Gamieldien, H. et. al. (2018). Inflammatory cytokine biomarkers of asymptomatic sexually transmitted infections and vaginal dysbiosis: a multicentre validation study. Sexually Transmitted Infections, 95 (1), 5–12. doi: http://doi.org/10.1136/sextrans-2017-053506
Campisciano, G., Zanotta, N., Licastro, D., De Seta, F., Comar, M. (2018). In vivo microbiome and associated immune markers: New insights into the pathogenesis of vaginal dysbiosis. Scientific Reports, 8 (1). doi: http://doi.org/10.1038/s41598-018-20649-x
Kirichenko, I. M. (2013). Ispolzovanie preparata Miramistin® pri infektsionnoi patologii v ginekologii. Poliklinika, 6, 98–100.
Mironova, A. V. (2016). Vozmozhnosti primeneniia preparata Miramistin® v praktike detskogo ginekologa (obzor literatury). Effektivnaia farmakoterapiia, 14, 42–46.
Copyright (c) 2021 Svitlana Pandei, Dmytro Ledin, Oleksandra Lubkovska
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.